Literature DB >> 10499479

Dietary analysis in symptomatic patients with coeliac disease on a gluten-free diet: the role of trace amounts of gluten and non-gluten food intolerances.

K B Faulkner-Hogg1, W S Selby, R H Loblay.   

Abstract

BACKGROUND: Whereas many people with coeliac disease (CD) are asymptomatic when consuming a gluten-free diet (GFD), a proportion continues to experience symptoms. The reasons for this are unclear.
METHODS: Thirty-nine adult members of The Coeliac Society of New South Wales, all of whom had persistent gastrointestinal symptoms despite adhering to a GFD, were evaluated. Dietary analysis indicated that 22 (56%) were consuming a GFD as defined by the WHO/FAO Codex Alimentarius (Codex-GFD), in which foods containing up to 0.3% of protein from gluten-containing grains can be labelled as 'gluten free'. The remaining 17 were following a no detectable gluten diet (NDG)-GFD, as defined by Food Standards Australia. All subjects were required to follow a NDG-GFD during the study. Those in whom symptoms persisted after changing from a Codex-GFD and those who entered the study already on a NDG-GFD began an elimination diet followed by open and double-blind challenges to identify specific non-gluten food or food chemical intolerances.
RESULTS: Of 22 patients who switched to a NDG-GFD symptoms resolved in 5 (23%) and were reduced in 10 others (45%). Thirty-one subjects commenced the elimination diet. Symptomatic improvement was experienced in 24 (77%). Subsequent food or food chemical challenges resulted in a mean of five positive challenges per individual. Diarrhoea was the most commonly provoked symptom, followed by headache, nausea, and flatulence. Symptoms were especially provoked by amine, salicylate and soy.
CONCLUSION: The consumption of trace amounts of gluten, traditionally allowed in a Codex-GFD, may be responsible for the continuing symptoms seen in some patients with CD. Further investigation for non-gluten food intolerances should follow if symptoms persist after adherence to a NDG-GFD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499479     DOI: 10.1080/003655299750025714

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

Review 1.  Pathogenesis of coeliac disease: implications for treatment.

Authors:  J S Fraser; P J Ciclitira
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

2.  Gut mucosal granulocyte activation precedes nitric oxide production: studies in coeliac patients challenged with gluten and corn.

Authors:  G Kristjánsson; M Högman; P Venge; R Hällgren
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Mucosal reactivity to cow's milk protein in coeliac disease.

Authors:  G Kristjánsson; P Venge; R Hällgren
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 4.  Complications of coeliac disease: are all patients at risk?

Authors:  C J R Goddard; H R Gillett
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

5.  A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet.

Authors:  D R Duerksen; C Wilhelm-Boyles; R Veitch; D Kryszak; D M Parry
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199

Review 6.  Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature.

Authors:  Mark Messina
Journal:  Nutrients       Date:  2016-11-24       Impact factor: 5.717

7.  Headache Associated with Coeliac Disease: A Systematic Review and Meta-Analysis.

Authors:  Panagiotis Zis; Thomas Julian; Marios Hadjivassiliou
Journal:  Nutrients       Date:  2018-10-06       Impact factor: 5.717

8.  Cow's milk protein sensitivity assessed by the mucosal patch technique is related to irritable bowel syndrome in patients with primary Sjögren's syndrome.

Authors:  M Lidén; G Kristjánsson; S Valtysdottir; P Venge; R Hällgren
Journal:  Clin Exp Allergy       Date:  2008-06       Impact factor: 5.018

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.